3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
8
Rectal Neoplasms
7
Neoplasm Metastasis
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Neutropenia
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastric Cancer Adenocarcinoma Metastatic
1
First-line Treatment
1
Esophageal Squamous Cell Carcinoma
1
EFS
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dihydropyrimidine Dehydrogenase Deficiency
×
trifluridine tipiracil drug combination
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled